Projects

Clinical Studies - Oct 18, 2023 - Dec 31, 2028

Ongoing

Project leader: Fischer Stefanie
Members: Harder Anja, Quinter Janine

Diese Studie wird durchgeführt, um mehr über AMG 509 als Monotherapie (Einzelmedikament) und AMG 509 in Kombination mit Abirateron oder Enzalutamid oder Pemb-rolizumab bei Patienten mit metastasiertem kastrationsre-sistentem Prostatakrebs (mCRPC) zu...

Clinical Studies - Nov 30, 2022 - Dec 31, 2026

Ongoing

Project leader: Fischer Stefanie
Members: Kern Julia, Quinter Janine

While many men diagnosed with locally confined disease may be treated definitively with radiation or surgery, ap-proximately 30% of men have recurrent disease and go on to develop metastatic prostate cancer. In addition, 5% to 30% of men with prostat...

Clinical Studies - Mar 3, 2020 - Mar 10, 2030

Ongoing

Project leader: Omlin Aurelius
Members: Rothermundt Christian, Aeppli Stefanie

Prostate cancer is the most frequent cancer in Western countries and castrate- resistant prostate cancer (CRPC) is its lethal form. Survival for CRPC patients with metastases now encompasses 30 months, while that for patients without metastases is ab...

Clinical Studies - Apr 26, 2019 - May 6, 2027

Ongoing

Project leader: Omlin Aurelius

Es handelt sich um eine randomisierte open label Phase III Studie. Die Patienten werden vom Hauptsitz der EORTC zentral im Verhältnis 1:1 für die Therapie mit Enzalutamid oder Enzalutamid (Standartbehandlung) und Ra223 (experi-mentelle Behandlung) r...

Clinical Studies - Oct 26, 2015 - Dec 31, 2030

Ongoing

Project leader: Rothermundt Christian
Members: Demmer-Steingruber Ruth, Quinter Janine

Background: Denosumab, a monoclonal antibody against RANK-Ligand has been shown to be superior to zoledronic acid in delaying time to a first on-study skeletal-related event (SRE) in patients with solid tumors, with no effects on disease progression...

Clinical Studies - Jul 7, 2014 - Dec 31, 2026

Ongoing

Project leader: Fischer Stefanie
Members: Sakic Miranda, Quinter Janine